Reverse Chemical Genetics: Comprehensive Fitness Profiling Reveals the Spectrum of Drug Target Interactions

PLoS Genetics

Volumn 12, Issue 9, 2016, Pages

  Wong, Lai H ^a   Sinha, Sunita ^a   Bergeron, Julien R ^b   Mellor, Joseph C ^c   Giaever, Guri ^a   Flaherty, Patrick ^d   Nislow, Corey ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SeqWell   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; METHOTREXATE; FOLIC ACID ANTAGONIST;

ARTICLE; BAYES THEOREM; BIOMICS; CELL MUTANT; CELL SURVIVAL; CHEMICAL GENETICS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG RESEARCH; DRUG RESISTANCE; DRUG SCREENING; DRUG TARGETING; FUNCTIONAL VARIOMICS; GENE FREQUENCY; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; IN VIVO STUDY; MUTATIONAL ANALYSIS; NONHUMAN; POINT MUTATION; STATISTICAL MODEL; STRUCTURE ACTIVITY RELATION; SYNTHETIC BIOLOGY; VALIDATION STUDY; ALLELE; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASMS;

ALLELES; BAYES THEOREM; DRUG RESISTANCE, NEOPLASM; FOLIC ACID ANTAGONISTS; HUMANS; METHOTREXATE; MUTATION; NEOPLASMS; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 84990193100     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1006275     Document Type: Article

References (60)

1. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG, Cancer drug resistance: an evolving paradigm. Nat Rev Cancer2013 print;13(10):714–726. doi: 10.1038/nrc359924060863
2. Cohen T, Jenkins HE, Lu C, McLaughlin M, Floyd K, Zignol M, On the spread and control of MDR-TB epidemics: An examination of trends in anti-tuberculosis drug resistance surveillance data. Drug Resistance Updates 2014 10; 2014;17(4):105–123.
3. Liu Y, Wang Y, Walsh TR, Yi L, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. The Lancet Infectious Diseases2016 /2;16(2):161–168. doi: 10.1016/S1473-3099(15)00424-726603172
4. Currie CJ, Berni E, Jenkins-Jones S, Poole CD, Ouwens M, Driessen S, et al. Antibiotic treatment failure in four common infections in UK primary care 1991–2012: longitudinal analysis. BMJ2014 09/23;349.
5. Garraway LA, Jänne PA, Circumventing Cancer Drug Resistance in the Era of Personalized Medicine. Cancer Discovery2012March01;2(3):214–226. doi: 10.1158/2159-8290.CD-12-001222585993
6. Wacker SA, Houghtaling BR, Elemento O, Kapoor TM, Using transcriptome sequencing to identify mechanisms of drug action and resistance. Nat Chem Biol2012 print;8(3):235–237. doi: 10.1038/nchembio.77922327403
7. Rodrigues JV, Bershtein S, Li A, Lozovsky ER, Hartl DL, Shakhnovich EI, Biophysical principles predict fitness landscapes of drug resistance. Proceedings of the National Academy of Sciences2016March15;113(11):E1470–E1478.
8. Villafranca JE, Howell EE, Voet DH, Strobel MS, Ogden RC, Abelson JN, et al. Directed mutagenesis of dihydrofolate reductase. Science1983 11/18;222(4625):782–788. 6356360
9. Lewis WS, Cody V, Galitsky N, Luft JR, Pangborn W, Chunduru SK, et al. Methotrexate-resistant Variants of Human Dihydrofolate Reductase with Substitutions of Leucine 22: KINETICS, CRYSTALLOGRAPHY, AND POTENTIAL AS SELECTABLE MARKERS. Journal of Biological Chemistry1995March10;270(10):5057–5064. 7890613
10. Cody V, Luft JR, Pangborn W, Understanding the role of Leu22 variants in methotrexate resistance: comparison of wild-type and Leu22Arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and NADPH. Acta Crystallographica Section D2005;D61:147–155.
11. Sun S, Yang F, Tan G, Costanzo M, Oughtred R, Hirschman J, et al. An extended set of yeast-based functional assays accurately identifies human disease mutations. Genome Research2016March14.
12. Hao G, Yang G, Zhan C, Structure-based Methods for Predicting Target Mutation-induced Drug Resistance and Rational Drug Design to Overcome the Problem. Drug Discov Today2012 07/10;17(19–20):1121–1126. doi: 10.1016/j.drudis.2012.06.01822789991
13. Carbonell P, Trosset J, Overcoming drug resistance through in silico prediction. Drug Discovery Today: Technologies; Drug Resistance2014 /3;11:101–107.
14. He Y, Zhang F, Flaherty P, RVD2: an ultra-sensitive variant detection model for low-depth heterogeneous next-generation sequencing data. Bioinformatics2015 04/07;31(17):2785–2793. doi: 10.1093/bioinformatics/btv27525931517
15. Barclay BJ, Huang T, Nagel MG, Misener VL, Game JC, Wahl GM, Mapping and sequencing of the dihydrofolate reductase gene (DFR1) of Saccharomyces cerevisiae. Gene1988;63(2):175–185. 2838386
16. Huang Z, Chen K, Zhang J, Li Y, Wang H, Cui D, et al. A functional variomics tool for discovering drug resistance genes and drug targets. Cell reports2013 02/14;3(2):577–585. doi: 10.1016/j.celrep.2013.01.01923416056
17. Cardenas ME, Cruz MC, Del Poeta M, Chung N, Perfect JR, Heitman J, Antifungal Activities of Antineoplastic Agents: Saccharomyces cerevisiae as a Model System To Study Drug Action. Clin Microbiol Rev1999 10;12(4):583–611. 10515904
18. Smith AM, Ammar R, Nislow C, Giaever G, A survey of yeast genomic assays for drug and target discovery. Pharmacol Ther2010 05/28;127(2):156–164. doi: 10.1016/j.pharmthera.2010.04.01220546776
19. Giaever G, Chu AM, Ni L, Connelly C, Riles L, Veronneau S, et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature2002 07/25;418(6896):387–391. 12140549
20. Boone C, Bussey H, Andrews BJ, Exploring genetic interactions and networks with yeast. Nat Rev Genet2007 print;8(6):437–449. 17510664
21. Pierce SE, Davis RW, Nislow C, Giaever G, Genome-wide analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in pooled cultures. Nat Protocols2007 print;2(11):2958–2974. 18007632
22. Fowler DM, Araya CL, Fleishman SJ, Kellogg EH, Stephany JJ, Baker D, et al. High Resolution Mapping of Protein Sequence-Function Relationships. Nature methods2010 08/15;7(9):741–746. doi: 10.1038/nmeth.149220711194
23. Hietpas RT, Jensen JD, Bolon DNA, Experimental illumination of a fitness landscape. Proceedings of the National Academy of Sciences2011May10;108(19):7896–7901.
24. Menacho-Márquez M, Murguía JR, Yeast on drugs: Saccharomyces cerevisiae as a tool for anticancer drug research. Clin Transl Oncol. 2007;9(4):221–228. 17462974
25. Wride DA, Pourmand N, Bray WM, Kosarchuk JJ, Nisam SC, Quan TK, et al. Confirmation of the cellular targets of benomyl and rapamycin using next-generation sequencing of resistant mutants in S. cerevisiae. Molecular bioSystems2014 12;10(12):3179–3187. doi: 10.1039/c4mb00146j25257345
26. Assaraf YG, Molecular basis of antifolate resistance. Cancer Metastasis Rev2007;26(1):153–181. 17333344
27. Zhao R, Goldman ID, Resistance to antifolates. Oncogene2003 print;22(47):7431–7457. 14576850
28. Bertino JR, Göker E, Gorlick R, Li WW, Banerjee D, Resistance Mechanisms to Methotrexate in Tumors. The Oncologist1996August 01;1(4):223–226. 10387992
29. Chunduru SK, Cody V, Luft JR, Pangborn W, Appleman JR, Blakley RL, Methotrexate-resistant variants of human dihydrofolate reductase. Effects of Phe31 substitutions. Journal of Biological Chemistry1994April01;269(13):9547–9555. 8144541
30. Ercikan-Abali EA, Mineishi S, Tong Y, Nakahara S, Waltham MC, Banerjee D, et al. Active Site-directed Double Mutants of Dihydrofolate Reductase. Cancer Research1996September15;56(18):4142–4145. 8797582
31. Chandran V, Siannis F, Rahman P, Pellett FJ, Farewell VT, Gladman DD, Folate Pathway Enzyme Gene Polymorphisms and the Efficacy and Toxicity of Methotrexate in Psoriatic Arthritis. The Journal of Rheumatology2010July01;37(7):1508–1512. doi: 10.3899/jrheum.09131120472929
32. Mclvor RS, Simonsen CC, Isolation and characterization of a variant dihydrofolate reductase cDNA from methotrexate-resistant murine L5178Y cells. Nucleic Acids Research1990January01;18(23):7025–7032. 2263462
33. Volpato JP, Yachnin BJ, Blanchet J, Guerrero V, Poulin L, Fossati E, et al. Multiple Conformers in Active Site of Human Dihydrofolate Reductase F31R/Q35E Double Mutant Suggest Structural Basis for Methotrexate Resistance. The Journal of Biological Chemistry2009 05/06;284(30):20079–20089. doi: 10.1074/jbc.M109.01801019478082
34. Patel M, Sleep EH, Lewis WS, Spencer HT, Mareya SM, Sorrentino BP, et al. Comparison of the Protection of Cells from Antifolates by Transduced Human Dihydrofolate Reductase Mutants. Human Gene Therapy2008;8(17).
35. Nakano T, Spencer HT, Appleman JR, Blakley RL, Critical role of phenylalanine 34 of human dihydrofolate reductase in substrate and inhibitor binding and in catalysis. Biochemistry1994;33(33):9945–9952. 8061003
36. Thompson PD, Freisheim JH, Conversion of arginine to lysine at position 70 of human dihydrofolate reductase: generation of a methotrexate-insensitive mutant enzyme. Biochemistry1991;30(33):8124–8130. 1907850
37. Fossati E, Volpato JP, Poulin L, Guerrero V, Dugas D, Pelletier JN, 2-Tier Bacterial and In Vitro Selection of Active and Methotrexate-Resistant Variants of Human Dihydrofolate Reductase. Journal of Biomolecular Screening2008July01;13(6):504–514. doi: 10.1177/108705710831878318566481
38. Gupta PB, Chaffer CL, Weinberg RA, Cancer stem cells: mirage or reality?Nat Med2009 print;15(9):1010–1012. doi: 10.1038/nm0909-101019734877
39. Zhou BS, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB, Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov2009 print;8(10):806–823. doi: 10.1038/nrd213719794444
40. Wintersberger U, Hirsch J, Induction of cytoplasmic respiratory deficient mutants in yeast by the folic acid analogue, methotrexate. Molecular and General Genetics MGG; 126(1):61–70. 4591370
41. Liu J, Bolstad DB, Smith AE, Priestley ND, Wright DL, Anderson AC, The crystal structure of Candida glabrata dihydrofolate reductase drives new inhibitor design toward efficacious antifungal agents. Chem Biol2008 09/22;15(9):990–996. doi: 10.1016/j.chembiol.2008.07.01318804036
42. Whitlow M, Howard AJ, Stewart D, Hardman KD, Chan JH, Baccanari DP, et al. X-ray Crystal Structures of Candida albicans Dihydrofolate Reductase: High Resolution Ternary Complexes in Which the Dihydronicotinamide Moiety of NADPH Is Displaced by an Inhibitor. J Med Chem2001 08/01;44(18):2928–2932. 11520201
43. Warren MS, Brown KA, Farnum MF, Howell EE, Kraut J, Investigation of the functional role of tryptophan-22 in Escherichia coli dihydrofolate reductase by site-directed mutagenesis. Biochemistry1991 11/01;30(46):11092–11103. 1932031
44. Davies JF, Delcamp TJ, Prendergast NJ, Ashford VA, Freisheim JH, Kraut J, Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate. Biochemistry1990 10/01;29(40):9467–9479. 2248959
45. McEntee G, Minguzzi S, O'Brien K, Ben LN, Loscher C, O'Fágáin C, et al. The former annotated human pseudogene dihydrofolate reductase-like 1 (DHFRL1) is expressed and functional. Proc Natl Acad Sci U S A2011 08/26;108(37):15157–15162. doi: 10.1073/pnas.110360510821876184
46. Gao J, Cui W, Du Y, Ji M, Insight into the molecular mechanism about lowered dihydrofolate binding affinity to dihydrofolate reductase-like 1 (DHFRL1). Journal of Molecular Modeling2013;19(12):5187–5198. 24122410
47. Palmer AC, Toprak E, Baym M, Kim S, Veres A, Bershtein S, et al. Delayed commitment to evolutionary fate in antibiotic resistance fitness landscapes. Nature communications2015 06/10;6:7385–7385. doi: 10.1038/ncomms838526060115
48. Skacel N, Menon LG, Mishra PJ, Peters R, Banerjee D, Bertino JR, et al. Identification of Amino Acids Required for the Functional Up-regulation of Human Dihydrofolate Reductase Protein in Response to Antifolate Treatment. Journal of Biological Chemistry2005June17;280(24):22721–22731. 15817466
49. Volpato JP, Pelletier JN, Mutational ‘hot-spots’ in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: Sequence and structural comparison. Drug Resistance Updates2009 0;12(1–2):28–41. doi: 10.1016/j.drup.2009.02.00119272832
50. Huang Z, Sucgang RS, Lin Y, Shi X, Boeke JD, Pan X, Plasmid-chromosome shuffling for non-deletion alleles in yeast. Nat Meth2008 print;5(2):167–169.
51. Pan X, Yuan DS, Xiang D, Wang X, Sookhai-Mahadeo S, Bader JS, et al. A Robust Toolkit for Functional Profiling of the Yeast Genome. Mol Cell2004 /11/5/;16(3):487–496. 15525520
52. Flaherty P, Natsoulis G, Muralidharan O, Winters M, Buenrostro J, Bell J, et al. Ultrasensitive detection of rare mutations using next-generation targeted resequencing. Nucleic Acids Res2011 09/26;40(1):e2–e2. doi: 10.1093/nar/gkr86122013163
53. Gietz RD, Schiestl RH, High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat Protocols2007 print;2(1):31–34. 17401334
54. Treco DA, Winston F, Growth and Manipulation of Yeast. Current Protocols in Molecular Biology: John Wiley & Sons, Inc.; 2001.
55. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 2.0. Bioinformatics2007November01;23(21):2947–2948. 17846036
56. Robert X, Gouet P, Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res2014 01/29;42:W320–W324. doi: 10.1093/nar/gku31624753421
57. Crooks GE, Hon G, Chandonia J, Brenner SE, WebLogo: A Sequence Logo Generator. Genome Research2004June01;14(6):1188–1190. 15173120
58. Eswar N, John B, Mirkovic N, Fiser A, Ilyin VA, Pieper U, et al. Tools for comparative protein structure modeling and analysis. Nucleic Acids Res2003 03/25;31(13):3375–3380. 12824331
59. Liu CT, Layfield JP, Stewart RJ, French JB, Hanoian P, Asbury JB, et al. Probing the Electrostatics of Active Site Microenvironments along the Catalytic Cycle for Escherichia coli Dihydrofolate Reductase. J Am Chem Soc2014 04/18;136(29):10349–10360. doi: 10.1021/ja503894724977791
60. Ashkenazy H, Erez E, Martz E, Pupko T, Ben-Tal N, ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Research2010July01;38(suppl 2):W529–W533.